Skip to main content



03-12-2018 | Canagliflozin | News

CANVAS analysis supports SGLT2 inhibitor benefits for HF

The latest analysis of the CANVAS trial indicates that the cardiovascular benefits of canagliflozin in patients with type 2 diabetes may be greatest in those with concomitant heart failure.

02-08-2018 | Cardiovascular outcomes | News

Further support for cardiovascular benefits of canagliflozin

Results of a US database study suggest that the sodium-glucose co-transporter-2 inhibitor canagliflozin is associated with a lower risk for heart failure hospitalization compared with three other classes of antidiabetes agent.

11-14-2017 | Canagliflozin | News

Canagliflozin benefits may extend to primary prevention

Further analysis of the CANVAS trial suggests that the benefits of canagliflozin treatment are broadly consistent in type 2 diabetes patients with and without pre-existing cardiovascular disease,

Read more

Related topics




11-22-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

In depth

08-22-2017 | Canagliflozin | Podcast | Audio

Dissecting the CANVAS trial

Listen to editorial board members and CANVAS investigators Carol Wysham and Lori Berard discussing the efficacy and safety findings of the trials.

Journal articles and book chapters

11-02-2017 | Heart failure | Review | Article

Treating disease mechanisms in patients with heart failure and diabetes mellitus

Trang A, Aguilar D. Curr Heart Fail Rep 2017; 14: 445–453. doi: 10.1007/s11897-017-0371-7

10-23-2017 | Insulin | Review | Article

Insulin and its cardiovascular effects: What is the current evidence?

This review discusses the key factors implicated in development and progression of cardiovascular disease, its relationship to insulin therapy, and what can be learned from large, recent cardiovascular outcome studies.

Dongerkery SP, Schroeder PR, Shomali ME. Curr Diab Rep 2017;17:120. doi:10.1007/s11892-017-0955-3

10-23-2017 | Cardiovascular disorders | Review | Article

Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: Recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

Schernthaner G et al. Cardiovasc Diabetol 2017; 16: 137. doi: 10.1186/s12933-017-0622-7

image credits